HVB MINI FUTURE BEAR - ASTRAZENECA | Real-time BOERSE MUENCHEN 09:45:42 2024-06-27 EDT | ||
| 0.58 EUR | +16.00% |
|
| Current month | -41.18% | ||
| 1 month | -31.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.58 | +16.00% |
| 24-06-26 | 0.5 | +2.04% |
| 24-06-25 | 0.49 | -14.04% |
| 24-06-24 | 0.57 | +3.64% |
| 24-06-21 | 0.55 | -16.67% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 09:45 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HB8552 |
| ISIN | DE000HB85522 |
| Date issued | 2022-07-01 |
| Strike | 12,931 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.25 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.01 € |
| Spread % | 1.39% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.04%
- Stock Market
- Certificates
- Certificat
